枯草杆菌二联活菌肠溶胶囊联合美沙拉嗪对溃疡性结肠炎患者的疗效及血清SOD MDA TNF-α的影响

doi:10.3969/j.issn.1006-6233.2018.12.003

Abstract
Figure/Table
References
Related Citation (8)

Download: PDF (1342 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the effect of bacillus subtilis adn enterococcus faecium enteric-coated capsule joint mesalazine on SOD, MDA, and TNF-α in patients with ulcerative colitis. Methods: 92 patients with ulcerative colitis was divided into research group (n=46) and control group (n=46) according to simple random methord. The control group was treated with mesalazine, qid. The study group was treated with mesalazine combined with Bacillus subtilis enteric-coated capsules, tid. The two groups were treated for 2 months. The clinical efficacy, colon inflammation and clinical symptom score, SOD, MDA, TNF-alpha, and adverse reactions were compared and observed between the two groups. Results: After treatment, the total effective rate of research group was 91.30% higher than the control group 76.08% (P<0.05). Colon inflammation score, clinical symptom scores, MDA, TNF -αof research group was lower than the control group (5.11±0.62)points, (0.64±0.08)points, (6.06±0.74) nmol/ml, (20.29±2.50) μg/L vs (7.80±0.93) points, (1.12±0.14) points, (7.23±0.92) nmol/ml, (23.76±2.88) μg/L, SOD of research group was higher than the control group (1.45±0.18) U/ml vs (1.28±0.16) U/ml (<0.05). The adverse reaction was not observed between two group (P>0.05). Conclusion: The effect of bacillus subtilis adn enterococcus faecium enteric-coated capsule joint mesalazine in treatment of ulcerative colitis is better than methadazine. It may be associated with better regulation of SOD, MDA, and TNF-α.

Key words： Ulcerative colitis Superoxide dismutase Mesalazine Malondialdehyde Bacillus subtilis adn enterococcus faecium enteric-coated capsule Tumor necrosis factor-α

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WENG Yan

Cite this article:

WENG Yan. Therapeutic Effect of Bacillus Subtilis combined with Mesalazine Enteric-coated Capsules on Patients with Ulcerative Colitis and the effects of serum SOD MDA and TNF-alpha[J]. HeBei Med, 2018, 24(12): 1945-1947.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.12.003 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I12/1945

[1] 唐勤富,曾伟.康复新液联合美沙拉嗪对老年溃疡性结肠炎患者炎性因子凝血功能的影响[J].现代中西医结合杂志,2016,25(26):2911~2913.
[2] Samsamikor M, Daryani NE, Asl PR, et al. Resveratrol supplementation and oxidative/anti-oxidative status in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study[J]. Arch Med Res,2016,47(4):304~309.
[3] 李建军,郭连凤,李建平,等.美沙拉秦、布拉氏酵母菌散和康复新液三联疗法治疗溃疡性结肠炎的效果[J].中国医药导报,2014,11(22):66~69.
[4] 张利利,赵英政,常廷民,等.枯草杆菌二联活菌胶囊对溃疡性结肠炎患者Th17/Treg细胞表达的影响[J].广东医学,2014,35(3):448~450.
[5] 中华医学会消化病学分会炎症性肠病协作组.对我国炎症性肠病诊断治疗规范的共识意见(2007年,济南)[J].中华消化杂志,2007,27(8):545~550.
[6] Har-Noy O, Kim B, Haiat R, et al. Combination of corticosteroids with 5-Aminosalicylic acids compared to corticosteroids alone for hospitalized patients with active ulcerative colitis[J]. Isr Med Assoc, 2016,18(10):613~618.
[7] 梁勇,颜丽萍,苏林,等.美沙拉嗪颗粒联合美常安胶囊对溃疡性结肠炎患者临床疗效及炎症反应的影响[J].现代生物医学进展,2016,16(23):4520~4522.
[8] 黄国栋,武艳,廖鹏,等.痛泻宁颗粒联合美沙拉秦口服治疗溃疡性结肠炎的疗效观察[J].重庆医学,2016,45(30):4261~4264.
[9] 张宏伟.枯草杆菌二联活菌肠溶胶囊治疗溃疡性结肠炎剂量探讨[J].中国乡村医药,2017,24(2):24~25.
[10] 黄志刚,刘有理,俞善春.美沙拉嗪联合双岐杆菌三联活菌治疗溃疡性结肠炎的疗效及对氧化应激、炎症因子的影响[J].海南医学院学报,2016,22(6):545~547.
[11] 吴中平,吴晓茹,徐意,等.中药保留灌肠联合美沙拉秦对溃疡性结肠炎患者血清肿瘤坏死因子-α、白细胞介素-6的影响[J].中国中西医结合消化杂志,2012,20(11):510~511.